Vitamin E
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Vitamin E
- Vitamin E: From Cholestasis-Related Vitamin E Deficiency to Inborn Disorder of Bilirubin Metabolism
Vitamin E: From Cholestasis-Related Vitamin E Deficiency to Inborn Disorder of Bilirubin Metabolism
One-Sentence Summary
Vitamin E is a fat-soluble antioxidant vitamin, originally used for cholestatic liver conditions and vitamin E deficiency. The TxGNN model predicts it may be useful for inborn disorder of bilirubin metabolism, but no clinical trials and only 1 indirectly related publication support this prediction, so it remains a model-driven hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cholestasis, benign recurrent intrahepatic cholestasis, familial intrahepatic cholestasis, familial isolated vitamin E deficiency (the Singapore licence texts list no approved indication) |
| Predicted New Indication | Inborn disorder of bilirubin metabolism |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, vitamin E (alpha-tocopherol) is a lipid-soluble antioxidant that limits lipid peroxidation in cell membranes. It is already used to correct fat-soluble vitamin deficiency in cholestatic liver disease.
The predicted indication is related to the original ones only loosely. The single supporting paper (PMID 7915305) describes a bile acid synthesis defect that causes progressive intrahepatic cholestasis. This is close to the cholestasis indications, but it is not a bilirubin metabolism disorder in the strict sense. Vitamin E repletion would treat secondary deficiency, not the underlying bilirubin metabolism defect. The very high TxGNN score most likely reflects network proximity to cholestasis in the knowledge graph rather than a specific mechanism.
A related "bilirubin metabolism disease" prediction (rank 2, score 99.99%) has somewhat more literature. It includes a small 1979 neonatal study of vitamin E in preterm infants with bilirubinemia (PMID 481976) and several reports of low plasma vitamin E in chronic liver disease. This evidence is old, indirect, and does not establish efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7915305 | 1994 | Case series | The Journal of Pediatrics | Screening of 30 children with progressive intrahepatic cholestasis (Byler disease) identified 3β-hydroxy-C27-steroid dehydrogenase/isomerase deficiency, a bile acid synthesis defect, as a new cause. It does not test vitamin E. |
For the closely related "bilirubin metabolism disease" prediction, the most relevant items are PMID 481976 (1979, a small neonatal study of intramuscular vitamin E in preterm infants with bilirubinemia) and PMIDs 3036938 and 3966426 (vitamin E deficiency in adults with chronic liver disease). None of these shows efficacy in an inherited bilirubin disorder.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN05207P | VITALIPID N INFANT INJECTION | Injection | Not listed in the data compiled for this report |
| SIN08875P | NEUROGEN-E TABLET | Tablet, film coated | Not listed in the data compiled for this report |
| SIN05208P | VITALIPID N ADULT INJECTION | Injection | Not listed in the data compiled for this report |
Safety Considerations
- Drug Interactions: 100 interactions were identified. The ones listed here are drawn from the first 20 returned entries, and the full list is not shown.
- Moderate: acetylsalicylic acid, iron, iron sucrose, sevelamer, and several anticoagulant or antiplatelet agents (abciximab, antithrombin III, apixaban, dipyridamole, betrixaban, bivalirudin, cangrelor, caplacizumab). Bleeding risk with antithrombotic agents deserves particular attention.
- Minor: corticosteroids (hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisone, prednisolone) and orlistat.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a very high model score, but there are no registered trials and only one indirectly related paper. Vitamin E would at most correct secondary deficiency and would not treat the bilirubin metabolism defect itself. Evidence is at L4, and the safety label data could not be retrieved.
To proceed, the following is needed:
- Singapore package insert warnings and contraindications from HSA
- Detailed mechanism of action data
- Disease-specific clinical or mechanistic evidence for inherited bilirubin metabolism disorders
- Clarification of which vitamin E products and routes would be relevant, since the registered products are multivitamin parenteral or oral supplements
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.